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We read with great interest the recent publication by 
Fehm and coworkers [1] about the association between 
the spread of circulating tumor cells (CTCs) and breast 
cancer subtypes. Th  e authors observed that the highest 
CTC positivity rate was obtained in triple-negative 
patients followed by those with estrogen receptor (ER)-
positive and/or progesterone receptor (PR)-positive 
tumors, while no CTCs could be detected in the human 
epidermal growth factor receptor 2 (HER2)-positive 
subtype group. However, another study [2] showed 
contradictory results, indicating that HER2 was the only 
primary tumor characteristic that correlated with the 
presence of CTCs, while ER and PR status were not 
association with their presence.
To clarify the correlation between CTCs and breast 
cancer subtypes, a total of 156 operable breast cancer 
patients admitted to our hospital were enrolled. Th  is 
study was approved by the regional ethics committee. 
Written informed consent was obtained from all partici-
pating patients. Mononuclear cell enrichment and CTC 
detection were done as previously described [3]. Th  e 
expression of ER, PR and HER2 in primary tumors was 
routinely detected.
Results showed that the overall positive rate of CTCs in 
operable breast cancer patients was 32.1% (50 out of 156). 
Th   ere existed signiﬁ  cant diﬀ  erences in the positive rate of 
CTCs between patients at diﬀ   erent pTNM stages 
(P = 0.0219) and between those with diﬀ  erent immuno-
histo  chemical subtypes (P = 0.0003). Further analysis 
revealed that the positive rate of CTCs in the HER2-
positive and triple-negative subtypes was signiﬁ  cantly 
higher than that of the luminal subtype (P=   0.0034 and 
0.0003, respectively). In subgroup analysis by pTNM 
stage, signiﬁ  cant diﬀ  erences in the positive rate of CTCs 
between patients with diﬀ  erent breast cancer subtypes 
were identiﬁ  ed at stages I (P = 0.0207), II (P = 0.0478) and 
III (P = 0.0324) (Table 1), further supporting that the 
presence of CTCs was associated with the HER2-positive 
and triple-negative subtypes.
In the present study, the presence of CTCs was more 
frequently found in patients with  HER2-positive and 
triple-negative subtypes than the luminal subtype, which 
might be ascribed to primary tumors of the former two 
subtypes being more aggressive histologically and having 
increased potential to be invasive, to migrate and to 
metastasize. In addition, recent research has suggested 
that the epithelial-mesenchymal transition plays a critical 
role in cancer progression, which could endow cancer 
cells with aggressive and stem cell-like properties, and 
pro  mote the dissemination of CTCs from the primary 
site to the circulation [4]. Most importantly, it has been 
shown that CTCs could express epithelial-mesenchymal 
transi  tion and/or cancer stem cell markers, which would 
support the hypothesis derived from the clinical data that 
CTCs are closely associated with distant metastasis in 
breast cancer patients [5]. Th  erefore, all these obser-
vations further support the need to clarify the correlation 
of primary tumor characteristics and CTCs in breast 
cancer patients.
In conclusion, our study suggests that the spread of 
CTCs was correlated with the HER2-positive and triple-
negative subtypes in breast cancer patients. Identifying  © 2010 BioMed Central Ltd
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Table 1. Correlation of CTCs and immunohistochemical 
subtypes of breast cancer in subgroup analysis by pTNM 
stage
 Luminal  HER2-positive  Triple-negative
 subtype  subtype  subtype
  CTC-  CTC-  CTC-
pTNM  positive Total positive Total positive Total 
stage  cases cases cases cases cases cases  Pa
I  2 23 1  6  4 10  0.0207b
II  7 38 5 10 8 18  0.0478
III  8 28 6  9  9 14  0.0324
aPearson’s χ2 test. bFisher’s exact test. CTC, circulating tumor cell.
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© 2010 BioMed Central Ltdpatients at higher risk of harboring CTCs would be 
helpful for the purpose of establishing the clinical values 
of CTCs as well as better evaluating the prognosis of 
breast cancer patients.
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